Osteochondral Allografts

Available exclusively from CONMED through MTF Biologics, osteochondral allografts with the Missouri Osteochondral Allograft Preservation System (MOPS℠) provide nearly double the storage-life with increased viable chondrocyte density.¹

• Higher Viable Cell Density¹

MOPS allografts maintained 98.8% viable cell density at 40 to 55 days, compared to Standard of Care (SOC) allografts, which maintained only 22.9% viable cell density at 21 to 28 days after procurement¹. Importantly, all MOPS allografts evaluated in the study had higher than the desired minimum essential viability level of 70%, while only 27% of SOC grafts evaluated exceeded the desired level at the time of implantation¹.

• Longer Shelf Life¹

MOPS allografts maintained 98.8% viable cell density at 40 to 55 days¹ – giving surgeons and their patients significantly more time to schedule the surgery. Meanwhile studies show that mean chondrocyte viability in osteochondral allografts stored using the current standard tissue bank protocols progressively declines and falls below the minimum essential level by 28 days from the time of procurement.^1.2

• Lower Revision Rates¹

MOPS allografts had a revision rate of only 2%, while the SOC allograft revision rate was 11.5%¹. Additionally, MOPS allografts had no early failures (6-24 months, mean = 12 months postop), compared to SOC allografts, which demonstrated an early failure rate of 3.8%.¹

• Patient-Matched Grafts

Due to the nature of this very desirable tissue and limited availability, MTF Biologics offers graft matching services specifically designed to provide orthopedic surgeons with the best possible anatomically matched allografts to meet each individual patient’s unique needs.³

_{¹Stoker et al. “Chondrocyte Viability at Time of Transplantation for Osteochondral Allografts Preserved by the Missouri Osteochondral Preservation System versus Standard Tissue Bank Protocol.” Journal of Knee Surgery. Volume 31, Issue 8, pp. 772-780, September 2018
²Cook et al. “Importance of Donor Chondrocyte Viability for Osteochondral Allografts.” The American Journal of Sports Medicine. Vol 44, Issue 5, pp. 1260 – 1268. February 26, 2016
³Data on File, MTF Biologics}